NBTXR3 First in Class Radioenhancer

Physical Mode of Action that could work across all solid tumors to enhance radiotherapy efficacy.

Only one administration

Fits into existing standard of care:

  • No change in equipment
  • No change in current patient flow
  • No change in protocol
  • One product addressing areas of high unmet medical needs.

    See more

    Recent Press Releases

    Nanobiotix to Announce Full Year 2021 Financial Results on March 30, 2022
    Nanobiotix Announces Publication of New Clinical Case Study Highlighting First Patient Experience of NBTXR3 Treatment for Pancreatic Cancer
    Nanobiotix Announces Publication of New Preclinical Immunotherapy Data Showcasing the Combination Potential of NBTXR3 with Anti-PD-1 and Anti-CTLA-4



    Scientific conference
    June 3, 2022

    2022 ASCO Annual Meeting

    More info
    global biotech finance events
    March 8

    Biomed Event®

    More info


    “Being part of Nanobiotix is a privilege. The privilege of exploring beyond the edge of science and challenging established and existing limits for the good of humankind. The privilege of being part of an extraordinary adventure to enable people to live a better life. The privilege of expanding life.”

    Anne-Juliette Hermant
    Chief People Officer

    Download our latest
    Corporate Presentation